GE Chairman’s Award Benefits FSH Muscular Dystrophy Research

Share Article

The $25,000 award to the Massachusetts-based FSH Society will fund scientific research grants focused on discovering and developing treatments for facioscapulohumeral muscular dystrophy.

"FSHD has impacted someone very dear to me, and I therefore wanted to do my part in helping to fund the research for finding a cure," Ehtashami told the FSH Society.

When GE Aviation’s Vice President Mohammad Ehteshami was told that he had received the prestigious GE Chairman’s Award, he asked that the $25,000 be donated to the FSH Society, a Massachusetts-based charitable foundation that has transformed the science of a little-known disease, facioscapulohumeral muscular dystrophy (FSHD).

"FSHD has impacted someone very dear to me, and I therefore wanted to do my part in helping to fund the research for finding a cure," Ehtashami told the FSH Society.

FSHD is one of the most common muscle dystrophies. The genetic disorder typically attacks the muscles of the face (facio), shoulder blades (scapula) and arms (humerus), but can progress to affect all skeletal muscles. Approximately one-quarter to one-third of patients end up in wheelchairs. FSHD affects more than half a million people around the world.

Every year, GE Chairman of the Board and CEO Jeff Immelt recognizes leaders from across the company with the annual Chairman's Awards for their outstanding performance and leadership. Those who receive the Chairman's Award have the honor of selecting a non-profit of their choice to receive a $25,000 monetary donation from GE.

This year, Ehteshami, who is Vice President for New Product Introduction Engineering Operations at GE Aviation, was recognized for his domain expertise and technology leadership in 2013.

"We congratulate Mr. Ehtashami on the recognition he has received from his company and are deeply honored that he chose the FSH Society to receive this generous donation,” said FSH Society Executive Director June Kinoshita. “FSHD is among the most prevalent muscular dystrophies, but is little known to the public, so corporate philanthropy is immensely important in helping to raise awareness and much-needed funds."

About the FSH Society
The FSH Society, founded in 1991 by two FSHD patients, is a world leader in combating muscular dystrophy. The non-profit has provided millions of dollars in seed grants to pioneering research worldwide, creating an international collaborative network of patients and researchers. The FSH Society seeks to serve as a source of information and support for all patients and families with FSHD; act as a driving force in the development of research directed towards treatments and ultimately a cure; and bring support to patients and research for FSHD through effective engagement of governmental and private sector organizations and entities. For five consecutive years, the Society has received the Charity Navigator’s four-star rating, the highest distinction held by less than four percent of non-profit organizations in the country. The FSH Society offers a community of support, news and information for FSHD patients and families through its website at For more information about FSHD, please contact the Society at 781-301-6649.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

June Kinoshita

Katherine Bragg
Visit website